Chiang Michael C, Satko Kathryn M, Shin Christina, Sperry Beau P, Cabral Meghan L, Crockett Zack, Gao Richard, Yong Robert J, Ang Samuel P, Burns Stacey L, Kim Alexander J
Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, USA.
Anesthesiology, University of Virginia, Charlottesville, USA.
Cureus. 2025 Jul 24;17(7):e88680. doi: 10.7759/cureus.88680. eCollection 2025 Jul.
Introduction The efficacy of stellate ganglion block (SGB) for managing post-acute sequelae of SARS-CoV-2 (PASC) remains an area of active exploration. In this study, we performed a retrospective analysis of PASC symptom improvements following SGB. Methods We performed a retrospective, survey-based cohort study at a single institution of patients with a history of PASC who underwent SGB at one of three different sites within Boston, MA, USA, between September 2022 and September 2024. The intervention was outpatient, office-based, with one or more unilateral SGBs. Results Fifty-two patients were included in the analysis. On average, patients underwent three SGB injections. Most patients reported improvement in PASC symptoms after SGB treatment. The most commonly reported symptoms that showed improvement were brain fog, fatigue, dizziness, and headache. A quarter of patients reported experiencing at least one adverse effect that was mostly short-lived. Conclusion SGB reduced the severity of many PASC symptoms, although there was high variability in the duration of symptom improvement. Further high-quality randomized clinical trials are warranted to investigate SGBs for the effective treatment of PASC.
引言 星状神经节阻滞（SGB）治疗新型冠状病毒2型（SARS-CoV-2）急性后遗症（PASC）的疗效仍是一个积极探索的领域。在本研究中，我们对SGB治疗后PASC症状的改善情况进行了回顾性分析。方法 我们在美国马萨诸塞州波士顿市三个不同地点之一接受SGB治疗的PASC病史患者的单一机构进行了一项基于调查的回顾性队列研究。干预措施为门诊、基于办公室的一次或多次单侧SGB。结果 52例患者纳入分析。患者平均接受了三次SGB注射。大多数患者报告SGB治疗后PASC症状有所改善。报告改善最常见的症状是脑雾、疲劳、头晕和头痛。四分之一的患者报告至少经历了一种主要为短暂性的不良反应。结论 SGB降低了许多PASC症状的严重程度，尽管症状改善的持续时间存在很大差异。有必要进行进一步高质量的随机临床试验，以研究SGB对PASC的有效治疗。
